BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Advanced Neuroscience Research

Executive Summary: BIIE 0246 is a potent and selective antagonist of the neuropeptide Y Y2 receptor (Y2R) with nanomolar affinity (IC₅₀ 3.3 nM), enabling precise blockade of presynaptic NPY signaling in central and peripheral models (APExBIO). It fully suppresses PYY_3-36-induced contractions in rat colon and reverses NPY-mediated inhibition of hippocampal synaptic activity (Doods et al., 1999, https://doi.org/10.1124/jpet.288.2.524). The compound modulates post-prandial satiety and produces anxiolytic-like effects in validated behavioral assays (Peptide-YY.com). BIIE 0246 is widely used to dissect the neuropeptide Y signaling pathway, which is increasingly implicated in metabolic regulation and cardiac arrhythmias (Fan et al., 2024). The B6836 kit from APExBIO provides high-purity material, with recommended storage at 4°C and validated solubility in DMSO and ethanol.

Biological Rationale

The neuropeptide Y (NPY) system is a key modulator of appetite, anxiety, and autonomic function. Y2 receptors (Y2R) are G protein-coupled receptors expressed throughout the brain and peripheral tissues. These receptors mediate presynaptic inhibition of neurotransmitter release, including their own ligand NPY, in a classic negative feedback loop (Fan et al., 2024). Dysregulation of NPY/Y2R signaling is linked to pathological feeding, stress responses, and arrhythmogenic processes via the adipose-neural axis. The selective inhibition of Y2R enables researchers to dissect these pathways without off-target effects seen in less selective antagonists (Unlocking the Translational Power of Y2 Receptor Antagonism). This article expands upon existing analyses by integrating the latest findings on NPY in cardiac and metabolic diseases.

Mechanism of Action of BIIE 0246

BIIE 0246 acts as a competitive antagonist at the neuropeptide Y Y2 receptor. It binds with high affinity (Ki 8–15 nM) to PYY_3-36 binding sites, effectively blocking endogenous and exogenous NPY and PYY action (APExBIO). The blockade of Y2R prevents presynaptic inhibition of neurotransmitter and NPY release, leading to increased synaptic transmission in targeted neural circuits. In hippocampal slices, BIIE 0246 reverses NPY-induced suppression of afterdischarge and excitatory postsynaptic potentials (EPSPs) (Doods et al., 1999). In peripheral tissues, it abolishes PYY_3-36-induced muscle contraction, confirming functional Y2R antagonism. Its anxiolytic-like effects in behavioral paradigms such as the elevated plus-maze further validate its central action (BIIE 0246: A Selective Y2 Receptor Antagonist for Advanced...).

Evidence & Benchmarks

• BIIE 0246 exhibits an IC₅₀ of 3.3 nM for Y2R and Ki values between 8–15 nM for specific PYY_3-36 binding in recombinant systems (APExBIO).
• In rat hippocampal slices, BIIE 0246 blocks NPY-induced inhibition of afterdischarge activity and population EPSPs, demonstrating presynaptic inhibitory effect blockade (Doods et al., 1999).
• It completely inhibits PYY_3-36-induced contraction in rat colon, confirming peripheral Y2R antagonism (Doods et al., 1999).
• BIIE 0246 attenuates PYY(3-36)-induced reduction in feeding in rats, demonstrating a role for Y2R in post-prandial satiety regulation (BIIE 0246: Unlocking Selective Y2 Receptor Antagonism...).
• The compound produces anxiolytic-like effects in the elevated plus-maze, supporting its central nervous system activity (BIIE 0246: A Selective Y2 Receptor Antagonist for Advanced...).
• NPY/Y2R signaling is implicated in the adipose-neural axis driving cardiac arrhythmias, providing a rationale for Y2R antagonists in translational cardiovascular research (Fan et al., 2024).

Applications, Limits & Misconceptions

BIIE 0246 serves as a reference tool for mapping Y2R-dependent circuits in feeding behavior, anxiety, and metabolic regulation. It is used in preclinical models to dissect the role of the neuropeptide Y signaling pathway in both central and peripheral systems. The compound enables studies on post-prandial satiety, synaptic plasticity, and behavioral modulation. Recent findings also position it as a probe for understanding the contribution of NPY/Y2R to the adipose-neural axis and cardiac arrhythmogenesis (Fan et al., 2024). This article extends prior work by providing updated benchmarks and clarifying the translational relevance compared to analyses such as Dissecting the Adipose-Neural Axis, offering a more detailed quantitative overview.

Common Pitfalls or Misconceptions

• Not a Y1 or Y5 antagonist: BIIE 0246 is selective for Y2 receptors and does not block Y1 or Y5 subtypes, which mediate distinct physiological effects (Doods et al., 1999).
• Not suitable for diagnostic or therapeutic use: The compound is for research applications only and should not be used in humans or animals for therapeutic purposes (APExBIO).
• Limited long-term stability in solution: Solutions are not stable for extended storage and should be freshly prepared for each experiment (APExBIO).
• Species and context dependency: Efficacy and specificity should be validated in each model system due to potential interspecies differences in Y2R pharmacology (BIIE 0246: Unraveling Y2 Receptor Antagonism in Neural-Ad...).
• No direct effect on leptin or Y1R pathways: While related to adipose-neural axis research, BIIE 0246 does not inhibit leptin signaling or Y1R, which are implicated in arrhythmogenesis (Fan et al., 2024).

Workflow Integration & Parameters

BIIE 0246 is provided as a white solid by APExBIO (B6836), with a molecular weight of 896.06 and formula C₄₉H₅₇N₁₁O₆. It is soluble up to 67.2 mg/ml in DMSO and 23.55 mg/ml in ethanol. Stock solutions should be prepared fresh and stored at 4°C; long-term storage is not recommended. The compound is compatible with both in vitro (e.g., brain slices, synaptosomes) and in vivo (rodent behavioral) paradigms. Dosage and protocol optimization is required for each application, with initial concentrations guided by published IC₅₀ and Ki values. For detailed protocols and advanced applications, see the product page for BIIE 0246 and recent method reviews (BIIE 0246: Unlocking Selective Y2 Receptor Antagonism for...).

Conclusion & Outlook

BIIE 0246 is a validated, high-affinity Y2R antagonist that enables precise manipulation of NPY-dependent pathways in neuroscience and metabolic research. Its robust selectivity and reproducible effects across models establish it as a gold standard for preclinical studies. Ongoing research into the adipose-neural axis and arrhythmogenesis continues to expand its utility. As new indications and mechanistic insights emerge, the BIIE 0246 (B6836) kit from APExBIO remains a cornerstone for experimental innovation and reproducibility. For further translational perspectives, see Unlocking the Translational Power of Y2 Receptor Antagonism, which this article updates with quantitative data and regulatory context.